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Abstract
Background: Sodium thiosulfate (STS) is an industrial chemical which has also been approved for the treatment of
certain rare medical conditions. These include cyanide poisoning and calciphylaxis in hemodialysis patients with
end-stage kidney disease. Here, we investigated the anti-inflammatory activity of STS in our glial-mediated
neuroinflammatory model.
Methods: Firstly, we measured glutathione (GSH) and hydrogen sulfide (H2S, SH
−) levels in glial cells after treatment
with sodium hydrosulfide (NaSH) or STS. We also measured released levels of tumor necrosis factor-α (TNFα) and
interleukin-6 (IL-6) from them. We used two cell viability assays, MTT and lactate dehydrogenase (LDH) release assays,
to investigate glial-mediated neurotoxicity and anti-inflammatory effects of NaSH or STS. We also employed Western
blot to examine activation of intracellular inflammatory pathways.
Results: We found that STS increases H2S and GSH expression in human microglia and astrocytes. When human
microglia and astrocytes are activated by lipopolysaccharide (LPS)/interferon-γ (IFNγ) or IFNγ, they release materials that
are toxic to differentiated SH-SY5Y cells. When the glial cells were treated with NaSH or STS, there was a significant
enhancement of neuroprotection. The effect was concentration-dependent and incubation time-dependent. Such
treatment reduced the release of TNFα and IL-6 and also attenuated activation of P38 MAPK and NFκB proteins. The
compounds tested were not harmful when applied directly to all the cell types.
Conclusions: Although NaSH was somewhat more powerful than STS in these in vitro assays, STS has already been
approved as an orally available treatment. STS may therefore be a candidate for treating neurodegenerative disorders
that have a prominent neuroinflammatory component.
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Background
Sodium thiosulphate (Na2S2O3, STS) is an industrial com-
pound which is typically available as the pentahydrate,
Na2S2O3 · 5H2O. It also has medical uses in the treatment
of some rare medical conditions. These include calciphy-
laxis in hemodialysis patients with end-stage kidney dis-
ease [1] as well as cyanide poisoning [2]. It also has
functions as a preservative in table salt (less than 0.1 %)
and alcoholic beverages (less than 0.0005 %). GMP prod-
ucts are widely available. While these amounts are very
small, they indicate that the general population is
consuming STS on a regular basis and increasing the dose
may have important therapeutic applications.
Recently, STS was demonstrated to function as an anti-
inflammatory agent [3]. For example, in acute liver failure
induced in mice by lipopolysaccharide (LPS) or LPS/D-
galactosamine, the survival rate was improved by hydro-
gen sulfide (H2S) and STS [4, 5]. STS is also reported to
protect neuronal cells from ischemia [6].
This at least is partially due to the antioxidative function
of these two agents; STS reacts with GSSG (oxidized
glutathione) to produce reduced glutathione in the pres-
ence of hydroxyl radicals or peroxides. In addition, STS
has a potential to produce hydrogen sulfide (H2S) by reac-
tion with trans-sulfuration enzymes [7–10].
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Previously, we reported that depletion of glutathione
(GSH) in glial cells induces neuroinflammation resulting in
neuronal death [11]. Neuroinflammation is, at least in part,
characterized by the microglial release of proinflammatory
factors such as cytokines and free radicals. Its purpose is to
remove the source of harm so healing can take place. But
when the inflammation is prolonged, it may cause neuronal
dysfunction and death [12]. Chronic neuroinflammation is
closely associated with the pathogenesis of several neurode-
generative diseases, including Alzheimer’s disease (AD) and
Parkinson’s disease (PD).
In earlier studies, we demonstrated that H2S or H2S-re-
leasing moieties, exhibited antioxidative, anti-inflammatory,
and neuroprotective properties [13–15]. In this investiga-
tion, we studied the effects of sodium hydrosulfide (NaSH)
or STS on SH-SY5Y neuronal cell death induced by super-
natants from LPS and interferon-γ (IFNγ)-activated glial
cells. These included cultured human astroglial and micro-
glial cells and human THP-1 and U373 cells.
We found that NaSH and STS generated H2S and GSH
in THP-1 and U373 cells, reduced release of proinflamma-
tory cytokines such as tumor necrosis factor-α (TNFα) and
interleukin-6 (IL-6) from LPS/IFNγ-stimulated microglia
and THP-1 cells, as well as IFNγ-stimulated astrocytes and
U373 cells. The toxicity was attenuated in a concentration-
dependent and incubation time-dependent manner. This
was due to reduced activation of intracellular inflammatory
pathways such as P38 MAPK and NFκB proteins.
Methods
Materials
All reagents were purchased from Sigma (St. Louis, MO)
unless stated otherwise. The following substances were
applied to the cell cultures: bacterial LPS (Escherichia coli
055:B5) and human recombinant IFNγ (Bachem Califor-
nia, Torrance, CA). Sodium thiosulfate anhydrous (STS)
was purchased from Sciencelab.com Inc. (Houston, TX).
Cell culture and experimental protocols
The human monocyte THP-1 and astrocytoma U373 cell
lines were obtained from the American Type Culture
Collection (Manassas, VA). The human neuroblastoma SH-
SY5Y cell line was a gift from Dr R. Ross, Fordham Univer-
sity, NY. These cells were grown in DMEM/F12 medium
containing 10 % fetal bovine serum (FBS) and 100 IU/mL
penicillin and 100 μg/mL streptomycin (Invitrogen, Carls-
bad, CA) under humidified 5 % CO2 and 95 % air.
Human astroglial and microglial cells were isolated from
surgically resected temporal lobe tissue as described previ-
ously [15]. Briefly, tissues were rinsed with a phosphate-
buffered saline (PBS) solution and chopped into small
(<2 mm3) pieces with a sterile scalpel. They were incu-
bated in 10 mL of a 0.25 % trypsin solution at 37 °C for
20 min. Subsequently, DNase I (from bovine pancreas,
Pharmacia Biotech, Baie d’Urfé, PQ, Canada) was added
to reach a final concentration of 50 μg/mL. Tissues were
incubated for an additional 10 min at 37 °C. After centrifu-
gation at 275g for 10 min, the cell pellet was resuspended
in the serum-containing medium and passed through a
100-μm nylon cell strainer (Becton Dickinson, Franklin
Lakes, NJ). The cell suspension was then centrifuged (275g
for 10 min), resuspended into 10 mL of Dulbecco’s modi-
fied Eagle medium (DMEM)-F12 with 10 % FBS containing
gentamicin (50 μg/mL), and plated onto tissue culture
plates (Becton Dickinson) in a humidified 5 % CO2, 95 %
air atmosphere at 37 °C for 2 h. This achieved adherence of
microglial cells. The non-adherent astrocytes along with
myelin debris were transferred into new culture plates. As-
trocytes adhered slowly and were allowed to grow by re-
placing the medium once a week. New passages of cells
were generated by harvesting confluent astrocyte cultures
using a trypsin–EDTA solution (0.25 % trypsin with EDTA,
Invitrogen, Carlsbad, CA). Human astrocytes from up to
the fifth passage from four surgical cases were used in the
study.
For estimating the purity of astrocytic and microglial cell
cultures, aliquots of the cultures were placed on glass slides
at 37 °C for 48 h. The attached cells were then fixed with
4 % paraformaldehyde for 1 h at 4 °C and permeablized
with 0.1 % Triton X-100 for 1 h at room temperature. After
washing twice with PBS, the astrocytic culture slides were
treated with a monoclonal anti-GFAP antibody (1/4,000,
DAKO) and the microglial slides with the polyclonal anti-
Iba-1 antibody (1/500, Wako Chemicals, Richmond, VA)
for 3 h at room temperature. The slides were then incu-
bated with Alexa Fluor 488-conjugated goat anti-mouse
IgG antibody (Invitrogen, 1:500) and Alexa Fluor 546-
conjugated goat anti-rabbit IgG antibody (Invitrogen,
1:500) in the dark for 3 h at room temperature to yield
red fluorescence for Iba-1 positive cells and green fluores-
cence for GFAP positive cells. To visualize all cells, the
slides were washed twice with PBS. Images were acquired
using an Olympus BX51 microscope and a digital camera
(Olympus DP71). Fluorescent images were colocalized
with ImagePro software (Improvision Inc., Waltham,
MA). We randomly chose 30 microscopic fields. Each
field contained a total of about 500 cells. The numbers of
astrocytes which appeared in microglial culture fields av-
eraged 3.11 ± 0.12 cells per field. The numbers of micro-
glia appearing in astrocytic culture fields was 2.05 ± 0.34
cells per field. The purity of microglia and astrocytic cul-
tures was more than 99 % (Fig. 1).
To achieve SH-SY5Y differentiation, the undifferentiated
cells were treated for 4 days with a high concentration of
retinoic acid (RA, 5 μM) in DMEM/F12 medium contain-
ing 5 % FBS, 100 IU/mL penicillin, and 100 μg/mL strepto-
mycin [16]. The RA-including medium was changed every
2 days. Differentiated SH-SY5Y cells demonstrated neurite
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extension, indicative of their differentiation [17], and act
like a fully-differentiated human neuron-like cells [18].
Experimental protocols
Protocol 1
Human astrocytes, U373 astrocytoma cells and THP-1
cells (5 × 105 cells), and human microglial cells (5 × 104
cells) were seeded into 24-well plates in 1 mL of DMEM/
F12 medium containing 5 % FBS. NaSH or STS was then
introduced at concentrations of 1 to 500 μM (the stock
solutions were prepared just before use with sterilized de-
ionized water). Incubation of the mixtures was carried out
for 2, 4, 8, or 12 h. Cells were washed with PBS twice and
replated in 800 μL DMEM/F12 medium containing 5 %
FBS. One set of cells was then incubated at 37 °C for 2 days
in the presence of inflammatory stimulants. For microglia
and THP-1 cells, the stimulants were LPS at 1 μg/mL and
IFNγ at 333 U/mL. For astrocytes and U373 cells, the
stimulant was IFNγ alone at 150 U/mL. A comparable set
of cells was incubated in media without inflammatory
stimulants. After incubation, the supernatants (400 μL)
were transferred to differentiated human neuroblastoma
SH-SY5Y cells (2 × 105 cells per well). The cells were incu-
bated for a further 72 h and 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) assays were per-
formed as described below.
Protocol 2
Since it is perceived that both NaSH and STS could be use-
ful as pharmaceutical agents, they must be shown to be
nontoxic to humans. To determine whether they were dir-
ectly affecting SH-SY5Y cell viability in the presence of
LPS/IFNγ-stimulated THP-1 conditioned medium (CM) or
IFNγ-stimulated U373 CM, NaSH or STS was added to a
glial cell supernatant (400 μL) just before the supernatants
were added to the SH-SY5Y cells. The glial cell superna-
tants were from THP-1 cells or U373 cells that had been
activated for 2 days with the inflammatory stimulants previ-
ously described. The subsequent procedures were the same
as in protocol 1.
SH-SY5Y cell viability assays
The viability of SH-SY5Y cells following incubation with
glial cell supernatants was evaluated by MTT assays as
previously described [19]. Briefly, the viability was deter-
mined by adding MTT to the SH-SY5Y cell cultures to
reach a final concentration of 1 mg/mL. Following a 1 h
incubation at 37 °C, the dark crystals formed were dis-
solved by adding a SDS/DMF extraction buffer (300 μL,
20 % sodium dodecyl sulfate, 50 % N,N-dimethylforma-
mide, pH 4.7). Subsequently, plates were incubated over-
night at 37 °C, and optical densities at 570 nm were
measured by transferring 100 μL aliquots to 96-well plates
and using a plate reader with a corresponding filter. Data
are presented as a percentage of the values obtained from
cells incubated in fresh medium only.
The viability of differentiated SH-SY5Y cells was investi-
gated by the lactate dehydrogenase (LDH) release assay
[19]. Briefly, cell culture supernatants (100 μl) were pipet-
ted into the wells of 96-well plates, followed by the
addition of 15 μl lactate solution (36 mg/ml in PBS) and
15 μl p-iodonitrotetrazolium violet (INT) solution (2 mg/
ml in PBS). The enzymatic reaction was started by
addition of 15 μl of NAD+/diaphorase solution (3 mg/ml
NAD+; 2.3 mg solid/ml diaphorase). After 1 h, optical
densities were measured with a Model 450 microplate
reader (Bio-Rad Laboratories, Richmond, CA) using a
490-nm filter. The amount of LDH released was expressed
Fig. 1 Immunofluorescence staining of Iba-1 (a, d red) in microglia and GFAP (b, e green) and merged images (c, f) in astrocytes in the microglial
(a–c) and astrocytic cultures (d–f). The results suggested that more than 99 % of cells prepared from human brains are microglia and astrocytes,
respectively. The calibration bar in F: 50 μm
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as a percentage of the value obtained in comparative wells
where cells were 100 % lysed by 1 % Triton X-100.
Measurement of TNFα and IL-6 release
Cytokine levels were measured in cell-free supernatants
following 48 h incubation of THP-1 cells, U373 cells,
microglial cells, and astrocytes. The cell stimulation proto-
cols in these experiments were the same as that used in
protocol 1. Quantitation was performed with ELISA de-
tection kits (Peprotech, NJ) following protocols described
by the manufacturer.
For determining TNFα and IL-6 depletion, protocols
published in earlier studies were followed [17, 20]. Briefly,
microglia were exposed to LPS/IFNγ, and astrocytes to
IFNγ, for 2 days. Their supernatants were transferred to
24-well plates which had been coated with anti-TNFα or
anti-IL-6 antibodies (10 mg/ml). After 3-h incubation, the
supernatants were transferred to SH-SY5Y cells. After in-
cubation at 37 °C for 3 days, MTT assays were performed
on the SH-SY5Y cells.
Activation of P38 MAPK and NFκB protein by Western
Blotting
Western blotting on cell lysates was performed as de-
scribed previously [19]. Briefly, microglia and astrocytes
were exposed to NaSH and STS at 100 μM for 8 h and
were subsequently exposed to stimulants for 2 h. Human
microglia and astrocytes were treated with a lysis buffer
(150 mm NaCl, 12 mm deoxycholic acid, 0.1 % Nonidet
P-40, 0.1 % Triton X-100, and 5 mm Tris-EDTA, pH 7.4).
The protein concentration of the cell lysates was then de-
termined using a BCA protein assay reagent kit (Pierce,
Rockford, IL). Proteins in each sample were loaded onto
gels and separated by 10 % sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) (150 V, 1.5 h).
The loading quantities of lysate proteins were 100 μg. Fol-
lowing SDS-PAGE, proteins were transferred to a PVDF
membrane (Bio-Rad, CA) at 30 mA for 2 h. The mem-
branes were blocked with 5 % milk in PBS-T (80 mm
Na2HPO4, 20 mm NaH2PO4, 100 mm NaCl, 0.1 % Tween
20, pH 7.4) for 1 h and incubated overnight at 4 °C with a
polyclonal anti-phospho-P38 MAP kinase antibody (9211,
Cell Signaling, Beverly, MA, 1/2,000) or anti-phospho-P65
NFκB antibody (3031, Cell Signaling, 1/1,000). The mem-
branes were then treated with a horseradish peroxidase-
conjugated anti-IgG (P0448, DAKO, Mississauga, Ontario,
CA, 1:2,000) or the secondary antibody anti-mouse IgG
(A3682, Sigma, 1/3,000) for 3 h at room temperature, and
the bands were visualized with an enhanced chemilumin-
escence system and exposure to photographic film
(Hyperfilm ECL™, Amersham Biosciences). Equalization of
protein loading was assessed independently using α-
tubulin as the housekeeping protein. The primary anti-
body was anti-α-tubulin (T6074, Sigma, 1/2,000) and the
secondary antibody anti-mouse IgG (A3682, Sigma, 1/
3,000). Primary antibody incubation was overnight at 4 °C,
and the secondary antibody incubation was for 3 h at
room temperature.
Measurement of H2S Levels
H2S (HS
−) levels were measured using a previously de-
scribed method [15]. To suppress endogenous production
of H2S by CBS, all experiments were done with 0.1 mM of
the specific CBS inhibitor hydroxylamine added to the so-
lutions. Two sets of experiments were conducted: one in
which the THP-1 cells and U373 cells were unstimulated
and a second where they were stimulated with inflamma-
tory mediators for 48 h. For THP-1 cells, the stimulation
was LPS at 1 μg/ml and IFNγ at 333 U/ml, and for U373
cells, it was IFNγ at 150 U/ml. The cells in each case were
treated with hydroxylamine plus NaSH or hydroxylamine
plus STS (100 μM each) for 2, 4, 8, and 12 h. Following
treatment, they were homogenized in 250 μl of ice-cold
100 mM potassium phosphate buffer (pH 7.4) containing
trichloroacetic acid (10 % w/v). Zinc acetate (1 % w/v,
250 μl) was injected to trap the generated H2S. A solution
of N,N-dimethyl-p-phenylenediamine sulfate (20 μM;
133 μl) in 7.2 m HCl and FeCl3 (30 μM; 133 μl) in 1.2 M
HCl was added. Absorbance at 670 nm of the resulting
mixture (300 μl) was determined after 10 min using a 96-
well microplate reader (Bio-Rad). The H2S concentration
of each sample was calculated against a calibration curve
of NaSH (1–500 μmol/ml). The protein concentration was
measured with a BCA protein assay reagent kit (Pierce,
Rockford, IL). The concentrations were expressed as mi-
cromole per gram protein.
Glutathione level
The GSH level was assessed by the method of Hissin and
Hilf [21] and Lee et al. [11]. This assay detects reduced
GSH by its reaction with o-phthalaldehyde (OPT) at pH
8.0. Cells (106) in 1.5-ml tubes were washed twice with
PBS, and 200 μl of 6.5 % trichloroacetic acid (TCA) was
added. The mixture was incubated on ice for 10 min and
centrifuged (13,000 rpm, 1 min). The supernatant was dis-
carded, and the pellets were resuspended in 200 μl of ice-
cold 6.5 % TCA and centrifuged again (13,000 rpm,
2 min). Supernatants (7.5 μl) were transferred to 96-well
plates containing 277.5 μl phosphate-EDTA buffer (pH
8.0) in 1 M NaOH solution. Then, 15 μl OPT (1 mg/ml in
methanol) was added. The reaction mixture was incubated
in the dark at room temperature for 25 min. The fluores-
cence at 350 nm excitation/420 nm emission was mea-
sured in a multiwell plate reader. The concentration was
calculated from a standard curve using serial dilutions of
reduced GSH. The concentration was expressed as micro-
mole per gram protein.
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Data analysis
The significance of differences between data sets was an-
alyzed by one-way or two-way ANOVA tests. Multiple
group comparisons were followed by a post hoc Bonfer-
roni test. P values are given in the figure legends.
Results
In these experiments, we compared NaSH with sodium
thiosulfate (STS). We firstly measured H2S (SH
−) and
GSH levels in THP-1 and U373 cells after treatment with
STS or NaSH. These cells are regarded as surrogate cells
of microglia and astrocytes. Intracellular H2S (SH
−) and
GSH concentrations were measured after treatment with
LPS/IFNγ for THP-1 cells and IFNγ for U373 cells
(100 μM each). STS and NaSH were exposed to the cells
for 0, 2, 4, 8, and 12 h. The results are shown in Fig. 2. In
both cell types, the H2S (SH
−) and GSH content increased
in an incubation time-dependent manner. However, the
levels were dramatically decreased when THP-1 cells were
exposed to LPS/IFNγ, and U373 cells to IFNγ, for 2 days.
For the NaSH groups, LPS/IFNγ treatment reduced both
H2S and GSH content in THP-1 cells by 75 % after 12 h.
IFNγ treatment reduced H2S and GSH by 80 and 85 %, re-
spectively, in U373 cells after 12 h. For STS groups, LPS/
IFNγ treatment reduced H2S and GSH by 75 and 90 %, re-
spectively, in THP-1 cells after in 12 h, and IFNγ treat-
ment reduced by 80 % in H2S and by 90 % in GSH in
U373 cells after 12 h. NaSH generated somewhat more
H2S (SH
−) and GSH than STS in both unstimulated and
stimulated cells. The data indicate that 12 h after NaSH or
STS treatment, substantial amounts of H2S (SH
−) and
GSH were still found in both types of cells after 2 days.
Therefore, we chose 2, 4, 8, and 12 h incubation time pe-
riods for further experiments.
Release of inflammatory cytokines
Inflammatory stimulation of microglia or THP-1 cells
causes them to release the inflammatory cytokines TNFα
and IL-6 [22, 23]. Figure 3 shows the effect on TNFα re-
lease by treatment of glial cells with NaSH and STS (1–
500 μM for 8 h pre-incubation, protocol 1). THP-1 release
of TNFα (Fig. 3a) and IL-6 (Fig. 3b) and human microglial
release of TNFα (Fig. 3c) and IL-6 (Fig. 3d) are illustrated.
The release of TNFα (Fig. 3a) and IL-6 (Fig. 3b) was
Fig. 2 Intracellular H2S (SH
−) and GSH concentrations produced from NaSH and STS in THP-1 cells (a, c) and U373 cells (b, d) with or without
stimulation for 2 days (for THP-1 cells: LPS/IFNγ and for U373 cells: IFNγ). NaSH and STS (100 μM each) were separately added to THP-1 cells. See
“Methods” section for details. Values are mean ± SEM, n = 4. Two-way ANOVA was carried out to test significance. Multiple comparisons were
followed with post hoc Bonferroni tests. a–d **P < 0.01 for STS-treated groups compared with NaSH groups in the same condition (without stimulants)
between 2 and 12 h, ##P < 0.01 for LPS/IFNγ- or IFNγ-activated groups compared with groups without stimulants between 2 and 12 h, ++P < 0.01 for
STS-treated groups compared with NaSH groups in the presence of stimulants between 2 and 12 h. Activation of both cells with stimulants dramatically
reduced H2S and GSH. NaSH was a somewhat more powerful agent than STS, but there was no qualitative difference between the two agents
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reduced by NaSH and STS exposure in a concentration-
dependent manner (Fig. 3, NaSH: P < 0.01 for 1 μM or
higher and for STS: P < 0.01 for 10 μM or higher). The in-
hibitory effects of NaSH were more powerful than STS (P
< 0.01 for 1 μM or higher and for TNFα and P < 0.01 for 3
μM or higher for IL-6). The IC50 values for NaSH and STS
shown in Table 1 (A, B) were confirmatory. The pattern
was similar in microglia (Fig. 3c, d). LPS/IFNγ stimulation
caused a 9.5-fold increase of TNFα and an 11-fold increase
of IL-6. Treatment with NaSH and STS reduced this release
(NaSH: 75 % and STS: 50–60 % at 500 μM, P < 0.01).
For astrocytes, IL-6 is the main inflammatory mediator
that is generated [24]. Figure 4 shows comparable data for
IL-6 release from U373 cells (Fig. 4a) and cultured astro-
cytes (Fig. 4b). Cells were activated with IFNγ according
to experimental protocol 1 and were then treated similarly
to the THP-1 and microglial cells shown in Fig. 3. The re-
lease of IL-6 was more than fourfold higher in primary
cultured astrocytes compared with U373 cells. However,
both compounds reduced the release of IL-6 from IFNγ-
activated U373 cells or astrocytes in a concentration-
dependent manner (P < 0.01 NaSH: P < 0.01 from 1 μM
and for STS: P < 0.01 from 10 μM). Again, NaSH is
stronger in reducing IL-6 release in both cell types (P <
0.01 from 1 μM). The IC50 values for NaSH and STS are
shown in Table 1 (C). NaSH is more potent than STS in
attenuating release of these cytokines.
We investigated, as described in methods, the direct ef-
fects of TNFα and IL-6 treatment, alone and in combin-
ation, on the viability of SH-SY5Y cells. MTT assays were
performed after 3 days incubation at 37 °C. There were no
changes in viability as shown in Fig. 5. However, the ef-
fects were different when the cells were exposed to
cytokine-depleted CM from microglia and astrocytes. For
depleted microglial conditioned medium (CM), the SH-
SY5Y viability was increased by 10.6 % for TNFα, 8.7 %
for IL-6, and 21 % for TNFα + IL-6 (Fig. 5a). For astro-
cytes, the corresponding increase in viability for IL-6 de-
pletion was 22 % (Fig. 5b).
Neuroprotective effect of NaSH and STS against
microglial, astrocytic, THP-1, and U373 cell toxicity
We investigated the effects of pre-treatment with NaSH
and STS on the toxicity of CM toward SH-SY5Y cells. The
CM was obtained by 2 days treatment of LPS/IFNγ-
Fig. 3 Effect of pre-treatment with NaSH or STS on released levels of TNFα (a, c) or IL-6 (b, d) from LPS/IFNγ-activated THP-1 cells (a, b) or LPS/
IFNγ-activated microglia (c, d). 8 h pre-incubation with NaSH or STS was performed before LPS/IFNγ was exposed to the cells for 2 days. Values
are mean ± SEM, n = 4. a, b Two-way ANOVA was carried out to test significance. Multiple comparisons were followed with post hoc Bonferroni
tests. +P < 0.01 for LPS/IFNγ-activated groups compared with control (CON) groups in each condition, *P < 0.01 for NaSH- or STS-treated groups
compared with LPS/IFNγ-activated groups, #P< 0.01 for STS-treated groups compared with NaSH groups in each condition. Note that both compounds
attenuated released levels of TNFα and IL-6 from both cell types in a concentration-dependent manner
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activated THP-1 cells and IFNγ-activated U373 cells. Ex-
perimental protocol 1 was followed.
It was found that NaSH and STS each attenuated SH-
SY5Y cell viability loss by THP-1 CM (Fig. 6). The effect
was concentration-dependent in the 1–500 μM range and
was time-dependent up to 12 h (Fig. 6a: 2 h pre-
incubation, 6b: 4 h pre-incubation, 6c: 8 h pre-incubation
and 6d: 12 h pre-incubation). At the shortest time interval
of 2 h and at the lowest concentration of 1 μM, the pro-
tective effect of NaSH was minimal. But the toxicity was
reduced to about half at a concentration of 500 μM (P <
0.01 from 1 μM). By 12 h the protective effect had in-
creased to the point where the lowest concentration re-
duced the toxicity by about one third while the highest
concentration reduced it by about five- to sixfold. Pre-
treatment with STS also attenuated THP-1 toxicity toward
SH-SY5Y cells at 2 h pre-incubation (P < 0.01 from
50 μM) but was less effective than NaSH (P < 0.01 from
3 μM); protective levels were 75 % of those obtained with
NaSH.
Figure 7 shows the effects of exposing SH-SY5Y cells to
the neurotoxic CM from U373 cells that had been stimu-
lated with 150 U of IFNγ according to experimental proto-
col 1. The figure shows highly similar data to those
obtained from stimulated THP-1 cells (Fig. 7a: 2 h pre-
incubation, 7b: 4 h pre-incubation, 7c: 8 h pre-incubation
and 7d: 12 h pre-incubation) were obtained. Again, the pro-
tective effect of the both agents was both concentration-
dependent and incubation time-dependent. NaSH was
more neuroprotective than STS (MTT test data: P < 0.01
Table 1 IC50 (μM) based on stimulated glial cell-released TNFα and IL-6 data of NaSH and STS at 8 h pre-incubation times
(A) TNFα: THP-1 cells and microglia
THP-1 cells Microglia
Pre-incubation time NaSH STS NaSH STS
8 h 31.15 ± 3.66 424.53 ± 18.25* 26.71 ± 4.32 579.53 ± 27.75*
(B) IL-6: THP-1 cells and microglia
THP-1 cells Microglia
Pre-incubation time NaSH STS NaSH STS
8 h 63.84 ± 7.95 621.53 ± 24.25* 33.36 ± 5.32 87.28 ± 6.79*
(C) IL-6: U373 cells and astrocytes
U373 cells Astrocytes
Pre-incubation time NaSH STS NaSH STS
8 h 432.26 ± 54.14 1356.53 ± 224.25* 7.44 ± 0.87 102.79 ± 11.25*
The tables summarized the IC50 results of the studies in Fig. 3 (Table 1 (A, B)) and Fig. 4 (Table 1 (C)). Values are mean ± SEM, n = 4. One-way ANOVA was carried
out to test significance. Note that there was a significant reduction in IC50 values of NaSH compared with those of STS in all groups
*P < 0.01
Fig. 4 Effect of pre-treatment with NaSH or STS on released levels of IL-6 from IFNγ-activated U373 cells (a) or IFNγ-activated astrocytes (b). 8 h
pre-incubation with NaSH or STS was performed before IFNγ was exposed to the cells for 2 days. Values are mean ± SEM, n = 4. a, b Two-way
ANOVA was carried out to test significance. Multiple comparisons were followed with post hoc Bonferroni tests. +P < 0.01 for LPS/IFNγ-activated
groups compared with CON groups for each condition, *P < 0.01 for NaSH- or STS-treated groups compared with LPS/IFNγ-activated groups,
#P < 0.01 for STS-treated groups compared with NaSH groups in each conditions. Note that both compounds attenuated released levels of IL-6
from both cell types in a concentration-dependent manner
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from 50 μM at 2 h, P < 0.01 from 30 μM at 4 h, P < 0.01
from 10 μM at 8 h, P < 0.01 from 3 μM at 12 h).
Table 2 summarized the IC50 results of these studies. As
shown in Figs. 6 and 7, the concentrations of NaSH re-
quired to reach the level of IC50, for both THP-1 and U373
cells, are approximately threefold lower than those required
for STS at all the incubation times in both THP-1 and
U373 cells. The data indicate that IC50s of NaSH and STS
are reduced with a longer pre-incubation time. The IC50s of
NaSH were at least three times lower than those of STS in
each pre-incubation time in both cell types.
We also investigated the effect of supernatants from
LPS/IFNγ-stimulated microglia and IFNγ-stimulated as-
trocytes on SH-SY5Y cell viability after treatment with
all the agents. Due to the limited availability of microglia
and astrocytes, they were pre-exposed to the compounds
at only one time period (8 h) prior to treatment with
stimulatory agents (experimental protocol 1). For meas-
uring SH-SY5Y cell viability, the MTT and LDH release
assays were utilized (upper panel: MTT assays and lower
panel: LDH release assays). It was observed that both
NaSH and STS reduced the toxicity of both LPS/IFNγ-
stimulated microglia (Fig. 8a) and IFNγ-stimulated astro-
cytes (Fig. 8b) toward SH-SY5Y cells (MTT assay data:
for NaSH: P < 0.01 from 1 μM and for STS: P < 0.01
from 10 μM). Again, NaSH had a greater neuroprotec-
tive effect than STS (MTT assay data: P < 0.01 from
1 μM) (Table 3). These data demonstrate that the effects
observed with cultured microglia and astrocytes are
comparable to those observed with the THP-1 and U373
cell lines.
However, pre-treatment with NaSH or STS of THP-1
cells and U373 cells for 12 h and of microglia and astro-
cytes for 8 h with both compounds did not change the via-
bility of any glial cells by stimulants (LPS/IFNγ for THP-1
cells and microglia: Additional file 1: Figure S1A and S1C,
and IFNγ for U373 cells and strocytes: Additional file 1:
Figure S1B and S1D).
It was also found that NaSH and STS were not directly
protective of SH-SY5Y cells (Additional file 1: Figure S2).
When they were added to the CM after stimulation had
taken place (protocol 2, A: THP-1 cells and B: U373 cells),
they had no effect. As the figure shows, there was no dif-
ference between the agents and there was no effect of con-
centration. This establishes that the agents were working
by inhibiting the glial inflammatory response.
In summary, NaSH and STS were not toxic to the glial
cells in the presence of inflammatory stimuli. The viability
of SH-SY5Y cells treated with the CM from LPS/IFNγ-
stimulated THP-1 and IFNγ-stimulated U373 cells was
unchanged.
As further control experiments, we tested the effects of
NaSH and STS on the growth and survival of human
microglia and astrocytes under normal and inflammatory
conditions. Human microglia and astrocytes were treated
with NaSH or STS for 3 days. MTT assays were then per-
formed on the cultures. Microglia and astrocytes were
next treated with stimulants plus NaSH or STS for 2 days.
The stimulants were LPS/IFNγ for microglia and IFNγ for
astrocytes. Comparative MTT assays were then performed
on the cultures. The results are shown in Additional file 1:
Figure S3. It was found that STS and NaSH did not
Fig. 5 a Contribution of TNFα and IL-6 released from LPS/IFNγ-stimulated microglia on SH-5Y5Y cell viability. Direct treatment of RA-differentiated
SH-SY5Y cells with TNFα (800 pg/ml) and/or IL-6 (600 pg/ml) was not changed SH-SY5Y cell viability (TNFa, IL-6, and TNFa + IL-6 in x-axis). Effects
of removing TNFα and/or IL-6 using their specific antibody (ELISA methods) from neurotoxic secretions from microglia stimulated with LPS/IFNγ
(TNFa Ab, IL-6 Ab, and TNFa Ab + IL-6 Ab in x-axis). CON and ST mean unstimulation and stimulation, respectively. See “Methods” section for details.
One-way ANOVA was carried out to test significance. *P < 0.01 vs CON group, **P < 0.01 vs ST group, and ***P < 0.01 vs TNFa Ab and IL-6 Ab groups.
b Contribution of IL-6 released from IFNγ-stimulated astrocytes on SH-5Y5Y cell viability. For details, see “Methods” section. Direct treatment of RA-
differentiated SH-SY5Y cells with IL-6 (120 ng/ml) was not changed SH-SY5Y cell viability (IL-6 in x-axis). Effects of removing IL-6 using their specific
antibody (ELISA methods) from neurotoxic secretions from astrocytes stimulated with IFNγ (IL-6 Ab in x-axis). CON and ST mean unstimulation and
stimulation, respectively. See “Methods” section for details. One-way ANOVA was carried out to test significance. *P < 0.01 vs CON group and **P < 0.01
vs ST group
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Fig. 6 Effect of treatment with NaSH or STS on SH-SY5Y cell viability changes induced by LPS/IFNγ-activated THP-1 cell conditioned medium
(CM) as followed by MTT and lactate LDH release assays (protocol 1). a 2 h pre-incubation, b 4 h pre-incubation, c 8 h pre-incubation, and d 12 h
pre-incubation. Upper panel: MTT assay data and lower panel: LDH release assay data. Values are mean ± SEM, n = 4. Two-way ANOVA was carried
out to test significance. Multiple comparisons were followed with post hoc Bonferroni tests. +P < 0.01 for LPS/IFNγ-activated groups compared
with CON groups in the same concentrations, *P < 0.01 for NaSH- or STS-treated groups compared with LPS/IFNγ-activated groups, #P < 0.01 for
STS-treated groups compared with NaSH roups in the same concentrations (a–d). Note that both compounds attenuated a reduction of SH-SY5Y
cell viability induced by LPS/IFNγ-activated THP-1 cell CM in a concentration-dependent and pre-incubation time-dependent manner
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Fig. 7 Effect of treatment with NaSH or STS on SH-SY5Y cell viability changes induced by IFNγ-activated U373 cell CM as followed by MTT and
LDH release assays (protocol 1). a 2 h pre-incubation, b 4 h pre-incubation, c 8 h pre-incubation, and d 12 h pre-incubation. Upper panel: MTT
assay data and lower panel: LDH release assay data. Values are mean ± SEM, n = 4. Two-way ANOVA was carried out to test significance. Multiple
comparisons were followed with post hoc Bonferroni tests. +P < 0.01 for LPS/IFNγ-activated groups compared with CON groups in the same
concentrations, *P < 0.01 for NaSH- or STS-treated groups compared with LPS/IFNγ-activated groups, #P < 0.01 for STS-treated groups compared
with NaSH groups at the same concentrations (a–d). Note that both compounds attenuated the reduction of SH-SY5Y cell viability induced by
IFNγ-activated U373 CM in a concentration-dependent and pre-incubation time-dependent manner
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change the viability of microglia and astrocytes under any
of the experimental conditions.
Activation of intracellular inflammatory pathway in
microglia and astrocytes
In the final set of experiments, we investigated the ef-
fects of pre-treatment with NaSH and STS at 100 μM
on phospho-P38 MAPK and phospho-NFκB proteins.
These are indicative of intracellular inflammatory activa-
tion. The data are shown in Fig. 9. Upon exposure to the
stimulants, both microglia and astrocytes showed an in-
crease in these proteins. For microglia, P38 MAPK was
increased sevenfold and NFκB eightfold. For astrocytes,
P38 MAPK and NFκB were increased sevenfold. Both
compounds attenuated these increases, and NaSH was
again more powerful than STS (NaSH: 80 % reduction
and STS: 60–65 % reduction).
Discussion
Brain damage is known to cause neuroinflammation by
activating microglia and astrocytes to release proinflam-
matory factors such as cytokines, toxic free radicals, and
proteases. Many previous publications indicate that oxi-
dative stress in neuronal cells plays an important role in
their death [25]. Indeed, we first reported that depletion
of GSH in both microglia and astrocytes induces neuro-
inflammation and results in neurotoxicity. It is known
that H2S is a reducing agent which can increase intracel-
lular glutathione levels. Glutathione is a major intracel-
lular antioxidant [26] and thereby inhibits oxidative
stress [11]. H2S activates adenylate cyclase to increase
[cAMP]i which has an inhibitory effect on transcription
of inflammatory cytokine mRNAs [26]. All of these
mechanisms may be contributing to the results reported
here.
In this study, we have shown that STS has the same
broad spectrum inhibition of toxic inflammatory activity
as NaSH. Since neuroinflammation has been demon-
strated to occur in degenerative neurological diseases such
as Alzheimer’s disease (AD) and Parkinson’s disease (PD)
[27, 28], STS is a potential therapeutic agent for these and
other neurodegenerative disorders. It has already been ap-
proved as a treatment for arsenic poisoning and calciphy-
laxis in hemodialysis patients with end-stage kidney
disease. This is at least partly due to an increase in H2S
and GSH in microglia and astrocytes by STS [7–10].
In these studies, we observed that the longer pre-
incubation time with STS and NaSH, the lower the con-
centrations of NaSH or STS to allow 50 % of SH-SY5Y cell
survival (IC50s) when exposed to their CMs. This corre-
lates with an increase in intracellular GSH and SH− levels
in both glial cell types (Fig. 2). Those increases inhibited
the proinflammatory pathways involving P38 MAP kinase
and NFκB proteins (Fig. 9). In turn, this led to production
and release of the proinflammatory factors TNFα and IL-6
(Figs. 3 and 4). The overall result was a decrease in loss of
SH-SY5Y cells in a concentration and pre-incubation
time-dependent manner (Figs. 6, 7, and 8). We found that
NaSH is more potent than STS (Tables 1, 2, and 3). This
is apparently due to higher levels of intracellular GSH and
SH− reached by NaSH compared with STS treatment.
In our previous experiments, we found that TNFα and
IL-6, alone and in combination, did not change SH-
SY5Y cell viability (Fig. 5). However, they enhanced SH-
Table 2 IC50 (μM) based on MTT (A-1 and B-1) and LDHR data (A-2 and B-2) of NaSH and STS at different pre-incubation times in
THP-1 cells and U373 cells
(A) MTT data
THP-1 cells U373 cells
Pre-incubation time NaSH STS NaSH STS
2 h 28.55 ± 2.32 121.53 ± 3.25 28.55 ± 3.32 95.53 ± 3.25
4 h 23.83 ± 2.34 96.47 ± 2.44 22.43 ± 3.34 49.63 ± 2.44
8 h 10.35 ± 2.11 53.55 ± 2.46 9.44 ± 2.11 30.27 ± 2.46
12 h 5.83 ± 1.47 35.73 ± 1.78 4.47 ± 1.83 19.57 ± 1.78
(A) LDHR data
THP-1 cells U373 cells
Pre-incubation time NaSH STS NaSH STS
2 h 15.33 ± 0.88 173.53 ± 18.75 32.48 ± 2.32 98.38 ± 7.25
4 h 3.83 ± 0.56 100.47 ± 12.44 25.18 ± 2.21 71.05 ± 4.44
8 h 2.11 ± 0.16 61.81 ± 5.46 10.17 ± 1.11 47.91 ± 3.46
12 h 1.42 ± 0.22 33.51 ± 2.31 1.84 ± 0.28 32.22 ± 2.78
The tables summarized the IC50 results of the studies in Figs. 6 and 7. Values are mean ± SEM, n = 4. Two-way ANOVA was carried out to test significance. Multiple
comparisons were followed with post hoc Bonferroni tests. Note that there was a significant reduction in IC50 values between any pre-incubation time groups and
that there was a significant reduction in IC50 values of NaSH compared with those of STS in the same incubation time groups
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SY5Y sensitivity to other inflammatory materials re-
leased from LPS/IFNγ-stimulated microglia and IFNγ-
stimulated astrocytes [17, 20].
Murutani et al. [6], in HPLC-linked measurements, re-
ported that treatment of SH-SY5Y cells with Na2S in-
creased intracellular and extracellular levels of thiosulfate,
but not H2S. In the current study, we measured H2S levels
in THP-1 and U373 cells with the zinc acetate-mediated
H2S-trap methods (i.e., methylene blue method). Given
the known limitation of this method that utilizes highly
acidic condition [29, 30], we were not able to measure
thiosulfate levels in the glial cells in this study.
It is known that direct inhalation of H2S is toxic even
though this gas is present in our body for a wide variety
Fig. 8 Effect of pre-treatment with NaSH or STS for 8 h on SH-SY5Y cell viability changes induced by a LPS/IFNγ-activated microglial CM and
b IFNγ-activated astrocytic CM as followed by MTT and LDH release assays (protocol 1). Upper panel: MTT assay data and lower panel: LDH release
assay data. Values are mean ± SEM, n = 4. Two-way ANOVA was carried out to test significance. Multiple comparisons were followed with post
hoc Bonferroni tests. +P < 0.01 for LPS/IFNγ- (a) or IFNγ-activated (b) groups compared with CON groups in each condition, *P < 0.01 for NaSH-
or STS-treated groups compared with LPS/IFNγ- or IFNγ-activated groups, #P < 0.01 for STS groups compared with NaSH groups in each condition.
Note that both compounds attenuated a reduction of SH-SY5Y cell viability induced by LPS/IFNγ-activated THP-1 cell CM in a
concentration-dependent manner
Table 3 IC50 (μM) based on MTT (A-1 and B-1) and LDHR data (A-2 and B-2) of NaSH and STS at different pre-incubation times in
microglia and astrocytes
Human microglia and astrocytes
(B) MTT data
Miroglia Astrocytes
Pre-incubation time NaSH STS NaSH STS
8 h 7.62 ± 0.46 68.43 ± 3.25 * 9.01 ± 0.71 77.53 ± 3.48 *
(B) LDHR data
Miroglia Astrocytes
Pre-incubation time NaSH STS NaSH STS
8 h 23.12 ± 1.46 51.43 ± 3.25 * 1.32 ± 0.11 53.06 ± 4.27 *
The tables summarized the IC50 results of the studies shown in Fig. 8. Values are mean ± SEM, n = 4. One-way ANOVA was carried out to test significance. Note that
there was a significant reduction in IC50 values of NaSH compared with those of STS
*P < 0.01
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of functions. STS was not itself toxic to any cell types up
to 500 μM under our experimental conditions. Further-
more, STS and NaSH did not affect the viability of any
glial cell type (Additional file 1: Figure S1–S3). There-
fore, both agents appear to be potentially suitable as
pharmaceutical drugs in conditions such as Alzheimer’s
disease and Parkinson’s disease.
Conclusions
In this report, we have shown NaSH and STS to be potent
anti-inflammatory agents and STS is 20–40 % less active
than NaSH in most assays, but there are no qualitative dif-
ferences and this would merely translate into modestly
higher doses to achieve the same effect. What is important
is that STS is an approved agent while NaSH must go
through many regulatory steps before it could be ap-
proved. For the present, emphasis should be on STS as a
potential broad spectrum therapeutic agent.
Additional file
Additional file 1: Figure S1. Effect of NaSH or STS on cell viability
changes after treatment for 2 days with LPS/IFNγ-activated THP-1 cells
(A), IFNγ-activated U373 cells (B), LPS/IFNγ-activated human microglia (C)
and IFNγ-activated human astrocytes (D) as followed by MTT assays. (A)
THP-1 cells and (B) U373 cells: 12 h preincubation with NaSH or STS and
(C) microglia and (D) astrocytes: 12 h preincubation with NaSH or STS.
Values are mean±SEM, n = 4. One-way ANOVA was carried out to test
significance. Multiple comparisons were followed with post-hoc Bonfer-
roni tests where necessary. Note that there was no viability change when
each compound was exposed to the cells in the presence of LPS/IFNγ or
IFNγ. Figure S2. Effect of treatment with NaSH and STS on SH-SY5Y cell
viability changes induced by LPS/IFNγ-activated THP-1 cell CM (A) or
IFNγ-activated U373 cell CM (B) as followed by MTT assays (Protocol 2). A:
THP-1 cells and B: U373 cells. After THP-1 cells and U373 cells were stimu-
lated for 2 days with LPS/IFNγ or IFNγ, respectively their supernatants
were transferred to SH-SY5Y cells. Then NaSH or STS was added. MTT
tests were performed after 3 days. Values are mean±SEM, n = 4. One-way
ANOVA was carried out to test significance. Multiple comparisons were
followed with post-hoc Bonferroni tests where necessary. Note that there
are no viability changes when all the compounds were exposed to SH-
SY5Y cells after LPS/IFNγ-activated THP-1 cell CM (A) or IFNγ-activated
U373 cell CM (B) were transferred. Figure S3. Effects of treatment with
NaSH and STS on microglial and astrocytic viability changes in the pres-
ence or absence of stimulants. (A) Microglia: no stimulation, (B) Astro-
cytes: no stimulation, (C) Microglia: Stimulation and (D) Astrocytes:
Stimulation. (A,B) After microglia and astrocytes were treated with STS
and NaSH for 3 days MTT assays were performed. (C,D) After microglia
and astrocytes were treated with STS and NaSH for 12 h stimulants were
added. After 2 day incubation MTT assays were performed. Values are
mean±SEM, n = 4. Note that NaSH and STS did not change SH-SY5Y cell
viability in the presence or absence of stimulants in any concentration
we tested. (DOC 99 kb)
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